[
  {
    "drug_name": "Metformin",
    "original_indication": "Type 2 Diabetes",
    "repurposed_cancer": [
      "Breast Cancer",
      "Prostate Cancer",
      "Endometrial Cancer"
    ],
    "confidence_score": 0.87,
    "evidence_level": "Multiple Phase II/III trials, observational data",
    "mechanism": "AMPK/mTOR inhibition, reduces insulin/IGF-1 signaling",
    "trial_count": 100,
    "phase": "Phase III",
    "citations": 500,
    "why_high_confidence": "Most studied diabetes drug in oncology, consistent epidemiological data",
    "pathways": [
      "AMPK activation",
      "mTOR inhibition",
      "Metabolic reprogramming"
    ],
    "sources": [
      "ReDO_DB",
      "ClinicalTrials.gov",
      "PubMed",
      "Broad Hub"
    ]
  },
  {
    "drug_name": "Aspirin",
    "original_indication": "Pain/Inflammation",
    "repurposed_cancer": [
      "Colorectal Cancer",
      "Lung Cancer"
    ],
    "confidence_score": 0.92,
    "evidence_level": "Preventive (approved in some guidelines), multiple trials",
    "mechanism": "COX inhibition, reduces prostaglandin synthesis, anti-platelet",
    "trial_count": 80,
    "phase": "Phase III/Preventive",
    "citations": 450,
    "why_high_confidence": "Reduces polyps, USPSTF recommendation for CRC prevention",
    "pathways": [
      "COX-2 inhibition",
      "Inflammation suppression",
      "Platelet aggregation"
    ],
    "sources": [
      "ReDO_DB",
      "USPSTF Guidelines",
      "ClinicalTrials.gov",
      "PubMed"
    ]
  },
  {
    "drug_name": "Ibuprofen",
    "original_indication": "Pain/Inflammation",
    "repurposed_cancer": [
      "Colorectal Cancer",
      "Breast Cancer"
    ],
    "confidence_score": 0.78,
    "evidence_level": "Observational studies + Phase II trials",
    "mechanism": "COX inhibition, similar to aspirin, anti-inflammatory",
    "trial_count": 45,
    "phase": "Phase II",
    "citations": 280,
    "why_high_confidence": "Similar mechanism to aspirin, large cohort studies",
    "pathways": [
      "COX-2 inhibition",
      "Inflammation reduction"
    ],
    "sources": [
      "ReDO_DB",
      "ClinicalTrials.gov",
      "PubMed"
    ]
  },
  {
    "drug_name": "Simvastatin",
    "original_indication": "Cardiovascular Disease (Hyperlipidemia)",
    "repurposed_cancer": [
      "Prostate Cancer",
      "Breast Cancer"
    ],
    "confidence_score": 0.81,
    "evidence_level": "Large cohort studies, Phase II trials",
    "mechanism": "Mevalonate pathway blockade, reduces cholesterol synthesis",
    "trial_count": 60,
    "phase": "Phase II",
    "citations": 320,
    "why_high_confidence": "Consistent epidemiological data, clear mechanism",
    "pathways": [
      "Mevalonate pathway",
      "Cholesterol synthesis",
      "RAS signaling"
    ],
    "sources": [
      "ReDO_DB",
      "ClinicalTrials.gov",
      "PubMed",
      "Broad Hub"
    ]
  },
  {
    "drug_name": "Atorvastatin",
    "original_indication": "Cardiovascular Disease (Hyperlipidemia)",
    "repurposed_cancer": [
      "Prostate Cancer",
      "Lung Cancer"
    ],
    "confidence_score": 0.79,
    "evidence_level": "Large cohort studies, ongoing trials",
    "mechanism": "Similar to simvastatin, mevalonate pathway inhibition",
    "trial_count": 55,
    "phase": "Phase II",
    "citations": 300,
    "why_high_confidence": "Most prescribed statin, large safety database",
    "pathways": [
      "Mevalonate pathway",
      "Cholesterol biosynthesis"
    ],
    "sources": [
      "ReDO_DB",
      "ClinicalTrials.gov",
      "PubMed"
    ]
  },
  {
    "drug_name": "Propranolol",
    "original_indication": "Hypertension",
    "repurposed_cancer": [
      "Angiosarcoma",
      "Various solid tumors"
    ],
    "confidence_score": 0.72,
    "evidence_level": "Case reports + Phase II trials",
    "mechanism": "Beta-blocker, reduces stress hormones, anti-angiogenic",
    "trial_count": 35,
    "phase": "Phase II",
    "citations": 180,
    "why_high_confidence": "Dramatic case reports in infantile hemangioma, stress reduction",
    "pathways": [
      "Beta-adrenergic blockade",
      "Angiogenesis inhibition"
    ],
    "sources": [
      "ReDO_DB",
      "ClinicalTrials.gov",
      "PubMed"
    ]
  },
  {
    "drug_name": "Itraconazole",
    "original_indication": "Antifungal",
    "repurposed_cancer": [
      "Lung Cancer",
      "Prostate Cancer",
      "Basal Cell Carcinoma"
    ],
    "confidence_score": 0.85,
    "evidence_level": "Phase II trials with positive signals",
    "mechanism": "Hedgehog pathway inhibition, angiogenesis inhibition",
    "trial_count": 40,
    "phase": "Phase II",
    "citations": 220,
    "why_high_confidence": "Clear Hedgehog pathway target, FDA-approved safety profile",
    "pathways": [
      "Hedgehog signaling",
      "Angiogenesis",
      "mTOR pathway"
    ],
    "sources": [
      "ReDO_DB",
      "ClinicalTrials.gov",
      "PubMed",
      "Broad Hub"
    ]
  },
  {
    "drug_name": "Valproic Acid",
    "original_indication": "Epilepsy",
    "repurposed_cancer": [
      "Leukemias",
      "Various hematologic malignancies"
    ],
    "confidence_score": 0.76,
    "evidence_level": "HDAC inhibitor activity, clinical use in combinations",
    "mechanism": "Histone deacetylase (HDAC) inhibition, epigenetic modulation",
    "trial_count": 50,
    "phase": "Phase II",
    "citations": 340,
    "why_high_confidence": "Known HDAC inhibitor, used in clinical combos",
    "pathways": [
      "HDAC inhibition",
      "Epigenetic regulation",
      "Differentiation"
    ],
    "sources": [
      "ReDO_DB",
      "ClinicalTrials.gov",
      "PubMed"
    ]
  },
  {
    "drug_name": "Thalidomide",
    "original_indication": "Sedative (later withdrawn, repurposed)",
    "repurposed_cancer": [
      "Multiple Myeloma"
    ],
    "confidence_score": 0.95,
    "evidence_level": "FDA-approved for multiple myeloma",
    "mechanism": "Immunomodulation, anti-angiogenic",
    "trial_count": 120,
    "phase": "Approved/Phase IV",
    "citations": 600,
    "why_high_confidence": "Fully approved and successful repurposing example",
    "pathways": [
      "Cereblon binding",
      "Angiogenesis inhibition",
      "Immune modulation"
    ],
    "sources": [
      "FDA",
      "ReDO_DB",
      "ClinicalTrials.gov",
      "PubMed"
    ]
  },
  {
    "drug_name": "Cimetidine",
    "original_indication": "Peptic Ulcer (H2 blocker)",
    "repurposed_cancer": [
      "Colorectal Cancer",
      "Gastric Cancer"
    ],
    "confidence_score": 0.71,
    "evidence_level": "Retrospective studies + Phase II trials",
    "mechanism": "Immune modulation, reduces suppressor T cells",
    "trial_count": 30,
    "phase": "Phase II",
    "citations": 150,
    "why_high_confidence": "Multiple retrospective analyses showing benefit",
    "pathways": [
      "T-cell activation",
      "Histamine receptor blockade"
    ],
    "sources": [
      "ReDO_DB",
      "ClinicalTrials.gov",
      "PubMed"
    ]
  },
  {
    "drug_name": "Digoxin",
    "original_indication": "Heart Failure",
    "repurposed_cancer": [
      "Breast Cancer",
      "Various solid tumors"
    ],
    "confidence_score": 0.68,
    "evidence_level": "Preclinical + early trials",
    "mechanism": "Na+/K+-ATPase inhibition, affects HIF-1\u03b1",
    "trial_count": 25,
    "phase": "Phase I/II",
    "citations": 120,
    "why_high_confidence": "Strong preclinical data, well-known safety profile",
    "pathways": [
      "HIF-1\u03b1 inhibition",
      "Na+/K+-ATPase"
    ],
    "sources": [
      "ReDO_DB",
      "Broad Hub",
      "PubMed"
    ]
  },
  {
    "drug_name": "Mebendazole",
    "original_indication": "Anthelmintic (parasitic worms)",
    "repurposed_cancer": [
      "Glioblastoma",
      "Various cancers"
    ],
    "confidence_score": 0.74,
    "evidence_level": "Preclinical + Phase I/II trials",
    "mechanism": "Tubulin inhibition, similar to vincristine",
    "trial_count": 20,
    "phase": "Phase II",
    "citations": 160,
    "why_high_confidence": "Crosses BBB, dramatic case reports in glioblastoma",
    "pathways": [
      "Microtubule disruption",
      "VEGF reduction"
    ],
    "sources": [
      "ReDO_DB",
      "ClinicalTrials.gov",
      "PubMed",
      "Broad Hub"
    ]
  },
  {
    "drug_name": "Doxycycline",
    "original_indication": "Antibiotic",
    "repurposed_cancer": [
      "Various cancers (MMP inhibition)"
    ],
    "confidence_score": 0.65,
    "evidence_level": "Preclinical + early trials",
    "mechanism": "Matrix metalloproteinase (MMP) inhibition, anti-metastatic",
    "trial_count": 18,
    "phase": "Phase I/II",
    "citations": 140,
    "why_high_confidence": "Well-tolerated, clear MMP inhibitor mechanism",
    "pathways": [
      "MMP inhibition",
      "Collagen synthesis"
    ],
    "sources": [
      "ReDO_DB",
      "PubMed",
      "Broad Hub"
    ]
  },
  {
    "drug_name": "Niclosamide",
    "original_indication": "Anthelmintic (tapeworm)",
    "repurposed_cancer": [
      "Colorectal Cancer",
      "Various cancers"
    ],
    "confidence_score": 0.7,
    "evidence_level": "Preclinical + Phase I/II",
    "mechanism": "Wnt/\u03b2-catenin pathway inhibition, mitochondrial uncoupling",
    "trial_count": 22,
    "phase": "Phase II",
    "citations": 180,
    "why_high_confidence": "Strong Wnt pathway inhibitor, multiple preclinical hits",
    "pathways": [
      "Wnt/\u03b2-catenin",
      "mTOR",
      "STAT3"
    ],
    "sources": [
      "ReDO_DB",
      "ClinicalTrials.gov",
      "PubMed",
      "Broad Hub"
    ]
  },
  {
    "drug_name": "Disulfiram",
    "original_indication": "Alcoholism (Antabuse)",
    "repurposed_cancer": [
      "Glioblastoma",
      "Various cancers"
    ],
    "confidence_score": 0.73,
    "evidence_level": "Phase I/II trials with copper",
    "mechanism": "ALDH inhibition, targets cancer stem cells",
    "trial_count": 28,
    "phase": "Phase II",
    "citations": 200,
    "why_high_confidence": "Targets cancer stem cells, active trials with copper",
    "pathways": [
      "ALDH inhibition",
      "Cancer stem cell targeting",
      "NF-\u03baB"
    ],
    "sources": [
      "ReDO_DB",
      "ClinicalTrials.gov",
      "PubMed"
    ]
  }
]